ALCAR not recommended anymore!

Alright, I've read through this study, and there are some important things we need to discuss before everyone panics about TMAO and throws their ALCAR in the trash. The first is the TMAO causation problem. Let's be very clear about something, there are zero human interventional trials showing TMAO itself causes cardiovascular disease. Every single study linking TMAO to CVD is observational/correlational. Multiple Mendelian randomization studies (which use genetics to infer causality) have found no causal relationship between TMAO and cardiovascular outcomes, stroke, or neurodegenerative disease. Some even found the reverse causation: that kidney disease and diabetes CAUSE elevated TMAO, not the other way around. The big elephant in the room? TMAO is renally cleared. People with kidney dysfunction have high TMAO. People with kidney dysfunction also have high CVD risk. When studies properly adjust for renal function (eGFR), the TMAO-CVD association often disappears or reverses. TMAO might just be a biomarker of kidney problems, not a causal agent. Also, what about fish? High-TMAO fish consumption is consistently associated with REDUCED cardiovascular risk, despite acutely elevating TMAO to similar levels. The "it's only bad when sustained" argument is a post-hoc rationalization with no experimental support in humans. We're essentially cherry-picking which TMAO elevation to be worried about based on the source, which is scientifically questionable. So yes, this study shows ~90% conversion to TMAO and plasma levels hitting 50 µM. That is notable and worth transparency, but let's not pretend we have proof that supplemental TMAO causes harm in humans. We don't.

Second, the bioavailability model is deeply flawed. This is where this study really misses the mark, especially for ALCAR. They measured plasma pharmacokinetics and concluded ALCAR has "significantly lower bioavailability than carnitine" (<5%) and that it's essentially useless. But they never measured:

* Brain tissue concentrations
* CSF levels
* Any functional cognitive outcomes
* Brain energy metabolism
* Neurotransmitter changes
* ANY pharmacodynamic endpoint

They saw low plasma AUC and assumed that means no tissue penetration or efficacy. That's a fundamental pharmacology error. Pharmacokinetics (what the body does to the drug) does not equal pharmacodynamics (what the drug does to the body). This reminds me of the NALT situation. Studies showed that NALT produces only a 25% increase in plasma tyrosine, with 56% excreted unchanged in urine. By plasma AUC logic, NALT is a terrible tyrosine supplement. Yet it's FDA-approved for parenteral nutrition, gets prescribed clinically, and many people (myself included) find it subjectively more effective than L-tyrosine for cognitive effects. Why? Because plasma tyrosine levels don't predict brain effects, nor does it address potential direct effects of NALT itself. Remember, heroin is diacetylmorphine. Heroin binds directly to the opioid receptors in the body. It's not just a prodrug for morphine by adding acetyl groups. It is its own thing entirely. The idea that NALT and ALCAR are just delivery systems for L-tyrosine and L-carnitine is equally flawed. Acetyltyrosine and acetylcarnitine likely have direct effects in the brain like acetylmorphine does.

So what evdience did they ignore for their conclusion? Direct human CSF studies show that oral ALCAR produces "significantly higher CSF levels than baseline, reflecting good penetration through the blood-brain barrier". OCTN2 transporters on brain capillary endothelial cells actively pump ALCAR from blood into brain tissue. Mass spectrometry imaging shows ALCAR distributes throughout brain regions after supplementation.

Brain tissue studies in rodents show that chronic ALCAR treatment (at doses equivalent to human 1.5g) produces:

* Increased ATP, phosphocreatine, and energy charge in cortex
* Elevated noradrenaline, serotonin, and dopamine
* 21-22% increase in regional cerebral glucose metabolism
* Improved mitochondrial function

Importantly, giving carnitine alone (without the acetyl group) produces none of these brain metabolic changes. This proves the acetyl group is the active moiety for cognitive effects, not total carnitine accumulation.

Clinical trials showing cognitive benefits at 1.5-3g doses:

* MCI meta-analysis: 21 studies showing significant improvements
* Alzheimer's disease: slowed cognitive decline
* Depression: ALCAR levels are significantly lower in depressed patients; supplementation effective
* The progressive decline in serum ALCAR from healthy (5.6 µM) → MCI (4.0 µM) → AD (3.5 µM) suggests these "low" plasma concentrations are functionally relevant

ALCAR isn't supposed to work by raising systemic carnitine levels. That's a fundamental misunderstanding of its mechanism. When ALCAR crosses into brain cells, carnitine acetyltransferase cleaves it into free carnitine + acetyl-CoA.

The acetyl-CoA is what matters. That synthesizes acetylcholine (your cognitive effects), enters TCA cycle for energy (bypassing rate-limiting steps), supports membrane lipid synthesis, drives protein acetylation (epigenetic effects). This is why ALCAR crosses the BBB better than carnitine. The brain wants the acetyl groups, not just more carnitine. Evaluating ALCAR as a "carnitine prodrug for systemic carnitine repletion" is like evaluating CDP-choline based on how much raw choline it produces in plasma. You're measuring the wrong thing.

What the study should have done:

* Measured brain tissue or CSF concentrations
* Included cognitive testing as a functional endpoint
* Compared to IV administration to calculate true bioavailability
* Extended dosing beyond single-dose to capture tissue accumulation

What they did:

* Measured plasma concentrations
* Assumed low plasma = no effect
* Concluded ALCAR is ineffective

This study showed that carnitine supplementation produces substantial TMAO elevation. That is true; even though causation for harm isn't established. People should be aware of this. However, the "low bioavailability therefore ineffective" conclusion for ALCAR is methodologically flawed. They measured the wrong compartment (plasma instead of brain), ignored direct CSF evidence, dismissed decades of clinical efficacy data, and fundamentally misunderstood ALCAR's mechanism. ALCAR works through acetyl-group donation in brain tissue, not by raising systemic carnitine levels. The study didn't look at the full picture. When we really look at the evidence on ALCAR, what do we see?

The evidence shows:

* ALCAR crosses the BBB more effectively than carnitine (Acetyl-L-carnitine in Alzheimer disease: a short-term study on CSF neurotransmitters and neuropeptides)
* The acetyl group is the active moiety for brain effects (Mechanisms of Ischemic Neuroprotection by Acetyl-L-carnitine)
* Brain energy metabolism and neurotransmitters change despite "low" plasma levels (Chronic acetyl-l-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice)
* Clinical cognitive benefits occur at these doses (Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update)(A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial for Efficacy of Acetyl-L-carnitine in Patients with Dementia Associated with Cerebrovascular Disease)(Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia)
* Giving carnitine alone doesn't replicate ALCAR's brain effects (L-Carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain)

TL;DR: There is currently no evidence that TMAO is harmful in humans, or if it is just a marker compound of other things that are harmful. That study didn't prove ALCAR has low efficacy.